Key result
The FGB rs1800790 polymorphism was significantly more frequent in patients with type 2 diabetes and heart failure with reduced ejection fraction compared to preserved ejection fraction (OR 7.71).
Why the study?
Studying genetic markers of hemostasis disorders in the development and progression of CHF in type 2 diabetes mellitus may aid prevention, optimize treatment, and improve prognosis.
Do genetic polymorphisms of coagulation factors differ between patients with type 2 diabetes mellitus and chronic heart failure with preserved versus reduced ejection fraction?
Observational (n=167)
Yes
Do genetic polymorphisms of coagulation factors differ between patients with type 2 diabetes mellitus and chronic heart failure with preserved versus reduced ejection fraction?
Odds Ratio: 7.71 (95% CI 1.86–11.95)
Absolute Event Rate: 53.9% vs 15.4%
p-value: p=<0.001
Patients with type 2 diabetes and HFrEF have a higher frequency of specific coagulation and cellular hemostasis gene polymorphisms compared to those with HFpEF or healthy controls.
May inform genetic risk assessment for CHF in DM2; leaves open whether polymorphisms predict progression or warrant targeted therapy.
BACKGROUND . Patients with type 2 diabetes mellitus (DM2) have disorders of cellular and plasma hemostasis independent of the level of glycemia, increased platelet activation, combined with microvascular angiopathy. The study of the role of genetic markers of hemostasis disorders in the formation and progression of chronic heart failure (CHF) in patients with type 2 diabetes will allow for prevention, possibly optimize treatment and improve prognosis. AIM . To reveal polymorphisms of genes of the hemostasis system in patients with type 2 diabetes mellitus and chronic heart failure with preserved ejection fraction. MATERIALS AND METHODS . The frequency of coagulation factor genetic polymorphisms was studied in patients with CHF-pEF and DM2 (52 people), CHF with reduced ejection fraction (CHF-rEF) and DM2 (49) and healthy volunteers (66), mean age 69.9±10.1 years old. DNA was isolated from venous blood according to the method of the manufacturer. Genetic polymorphisms were determined by real-time polymerase chain reaction. RESULTS . The frequencies of polymorphisms rs1799963 and rs6025 of the genes of blood coagulation factors F2 (prothrombin) and F5 (factor V of blood coagulation) in all three groups were insignificant and comparable in magnitude. In patients with CHF and DM2, the frequencies of the rs6046 polymorphism of the factor F7 gene in the heterozygous form were slightly higher (by 2.6 and 1.7 times, respectively) than in the control group, but the result was not statistically significant. The CHF-pEF and CHF-rEF groups differ in the frequencies of F13 (rs5985) and fibrinogen (rs1800790) genetic polymorphisms, but are more common in patients with CHF-rEF and DM2. CONCLUSION . Based on the results of the study, it follows that the groups of CHF-pEF and CHF-rEF differ significantly in the frequencies of polymorphisms of the studied genes, both among themselves and with the control group. The highest frequency of polymorphisms of genes, the products of which are involved in the coagulation and cellular components of hemostasis, is observed in the group of patients with DM2 and CHF-rEF.
No takes yet. Share an insight, caveat, or question.
Свеклина et al. (2023) conducted an observational in Type 2 diabetes mellitus and chronic heart failure (n=167). Coagulation factor genetic polymorphisms (e.g., FGB rs1800790) vs. Patients with preserved ejection fraction or healthy volunteers was evaluated on Frequency of FGB rs1800790 polymorphism (risk alleles) (OR 7.71, 95% CI 1.86-11.95, p=<0.001). The FGB rs1800790 polymorphism was significantly more frequent in patients with type 2 diabetes and heart failure with reduced ejection fraction compared to preserved ejection fraction (OR 7.71).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: